High drug attrition rates—where are we going wrong?


Drug attrition rates for cancer are much higher than in other therapeutic areas. Only 5% of agents that have anticancer activity in pre clinical develop ment are licensed after demonstrating sufficient efficacy in phase III testing, which is much lower than, for example, 20% for cardiovascular disease. To compound this issue, many new cancer agents are… (More)
DOI: 10.1038/nrclinonc.2011.34


1 Figure or Table